High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma-Reference-Cited by-同舟云学术

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma

Published:2024-07 Issue: Volume:186 Page:42-52
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Hollis Robert L.,Elliott Richard,Dawson John C.,Ilenkovan Narthana,Matthews Rosie M.,Stillie Lorna J.,Oswald Ailsa J.,Kim Hannah,Llaurado Fernandez Marta,Churchman Michael,Porter Joanna M.,Roxburgh Patricia,Unciti-Broceta Asier,Gershenson David M.,Herrington C. Simon,Carey Mark S.,Carragher Neil O.,Gourley Charlie

Funder

Cancer Research UK

Nicola Murray Foundation

Target Ovarian Cancer

Publisher

Elsevier BV

Reference39 articles.

1. Low-grade serous ovarian cancer: state of the science;Slomovitz;Gynecol. Oncol.,2020

2. Molecular characteristics and clinical behaviour of epithelial ovarian cancers;Hollis;Cancer Lett.,2023

3. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data;Irodi;BJOG,2020

4. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase;Grabowski;Gynecol. Oncol.,2016

5. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum;Schmeler;Gynecol. Oncol.,2008

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular changes driving low-grade serous ovarian cancer and implications for treatment;International Journal of Gynecologic Cancer;2024-06-30